An official website of the United States government
Home
| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C9301 | Obecabtagene car pos t (Obecabtagene autoleucel) | AUCATZYL | up to 400 million | Immunotherapy | CAR-T | CD-19 | No | 2024 | Mar 26, 2025 | Jul 9, 2025 | No Longer Used | |
| J9382 | Zenocutuzumab-zbco | Bizengri | 1mg | Immunotherapy | Bispecific Antibody | HER2, HER3 | No | 2024 | Jul 9, 2025 | In Use | ||
| J0870 | Imetelstat | Rytelo | 1mg | Chemotherapy | Enzyme Inhibitor | Telomerase | No | 2024 | Dec 17, 2024 | In Use | ||
| J9076 | Cyclophosphamide (Baxter) | Cyclophosphamide (Baxter) | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2024 | Dec 17, 2024 | In Use | ||
| Q2057 | Afamitresgene autoleucel | Tecelra | per therapeutic dose | Immunotherapy | T Cell Receptor (TCR) | MAGE-A4 | No | 2024 | Mar 26, 2025 | In Use | ||
| Q5136 | Denosumab-bbdz | Jubbonti/Wyost | 1mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2024 | Sep 11, 2024 | In Use | ||
| Lazertinib | Lazcluze | 80mg, 240mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2024 | In Use | ||||
| Vorasidenib | Voranigo | 10mg,40mg | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Yes | 2024 | In Use | ||||
| C9303 | Zolbetuximab-clzb | Vyloy | 1mg | Immunotherapy | Monoclonal Antibody | CLDN18.2 | No | 2024 | Mar 26, 2025 | Jul 9, 2025 | No Longer Used | |
| Revumenib | Revuforj | 25mg, 110mg, 160mg | Chemotherapy | Enzyme Inhibitor | KMT2A | Yes | 2024 | In Use | ||||
| Inavolisib | Itovebi | 3mg, 9mg | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Yes | 2024 | In Use | ||||
| Tovorafenib | Ojemda | 25mg, 100mg | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | Yes | 2024 | In Use | ||||
| J9329 | Tislelizumab-jsgr | Tevimbra | 1mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2024 | Sep 11, 2024 | In Use | ||
| J9054 | Bortezomib (boruzu) | Boruzu | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2024 | Mar 26, 2025 | In Use | ||
| Inovolisib | Itovebi | 3mg, 9mg | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Yes | 2024 | In Use | ||||
| J9174 | Docetaxel (beizray) | Beizray | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2024 | Jul 9, 2025 | In Use | ||
| C9173 | Filgrastim-txid (nypozi) | Nypozi | 1 mcg | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | No | 2024 | Dec 17, 2024 | Jul 9, 2025 | In Use | |
| Q5148 | Filgrastim-txid (nypozi) | Nypozi | 1 microgram | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | No | 2024 | Mar 26, 2025 | In Use | ||
| Q2058 | Obecabtagene autoleucel | AUCATZYL | up to 400 million | Immunotherapy | CAR-T | CD-19 | No | 2024 | Jul 9, 2025 | In Use | ||
| J9026 | Tarlatamab-dlle | IMDELLTRA | 1mg | Immunotherapy | T Cell Receptor (TCR) | DLL3, CD3 | No | 2024 | Dec 17, 2024 | In Use | ||
| J9024 | Atezolizumab, hyaluronidase-tqjs | Tecentriq Hybreza | 5mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2024 | Mar 26, 2025 | In Use | ||
| J9276 | Zanidatamab-hrii | ZIIHERA | 2mg | Immunotherapy | Bispecific Antibody | HER2 | No | 2024 | Jul 9, 2025 | In Use | ||
| C9170 | Tarlatamab-dlle, 1 mg | IMDELLTRA | 1mg | Immunotherapy | T Cell Receptor (TCR) | DLL3, CD3 | No | 2024 | Sep 11, 2024 | Dec 17, 2024 | No Longer Used | |
| C9302 | Zanidatamab-hrii | ZIIHERA | 2mg | Immunotherapy | Bispecific Antibody | HER2 | No | 2024 | Mar 26, 2025 | Jul 9, 2025 | No Longer Used | |
| J9275 | Cosibelimab-ipdl | UNLOXCYT | 2mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2025 | Jul 9, 2025 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
